Endure Biotherapeutics

Executive Summary

Endure Biotherapeutics is a preclinical-stage biotechnology company pioneering a novel platform for engineering native bacterial strains that engraft persistently in the human gut. Founded in 2020 and based in Cambridge, MA, the company aims to develop live biotherapeutics for genetic and chronic diseases by leveraging bacteria that naturally colonize the intestine, enabling long-term therapeutic effects with reduced dosing frequency. Unlike traditional microbiome approaches that rely on transient probiotics, Endure's proprietary engineering platform modifies commensal strains to express therapeutic payloads in situ, potentially overcoming key challenges of stability and durability. The company's lead programs target metabolic and inflammatory disorders, with a focus on conditions where continuous drug exposure is critical. While still in early research stages, Endure's technology could represent a paradigm shift in drug delivery by turning the gut into a sustainable drug factory. The company's progress depends on advancing preclinical validation and securing financing to move toward clinical development.

Upcoming Catalysts (preview)

• Q4 2026Lead Program Nomination & Preclinical POC Data40% success
• H1 2027Series A or B Financing Round60% success
• Q2 2027IND-Enabling Studies Initiation30% success